Pharma major Dr Reddy’s Laboratories Ltd has entered into a strategic collaboration agreement with Turkey-based TR-Pharm involving three biosimilar products. The company issued a statement saying, “We have entered into a strategic collaboration agreement with Turkey-based TR-Pharm involving 3 biosimilar products. These products will be registered and subsequently commercialised as a part of this agreement by TR-Pharm in Turkey.”
TR-Pharm will also manufacture the drug substance and drug product upon completion of its facility investment, the release said.
TR-Pharm has begun laying out the groundwork for the technology transfer. This collaboration will be an important component of TR-Pharm’s ongoing biological product development and manufacturing business in the region. The partnership will also enable Dr. Reddy’s to widen the global footprint of its biosimilar business.
TR-Pharm General Manager Mehmet Goker said, “Biosimilars are a key component of our investment strategy in Turkey to establish biotechnological API production for national use and regional exports. This agreement will not only enable more affordable medication but also support our research and development initiatives by building expertise within the country.”
M V Ramana, Executive Vice President & Head Branded Markets (India and Emerging countries) of Dr Reddy’s added, “Turkey is a key emerging market and we are pleased to partner with TR-Pharm to ensure that patients in the region get access to our portfolio of high quality biosimilar products.
“
